These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

462 related articles for article (PubMed ID: 26774923)

  • 1. Design, synthesis, and biological evaluation of novel thiazolidinediones as PPARγ/FFAR1 dual agonists.
    Darwish KM; Salama I; Mostafa S; Gomaa MS; Helal MA
    Eur J Med Chem; 2016 Feb; 109():157-72. PubMed ID: 26774923
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Homology modeling and explicit membrane molecular dynamics simulation to delineate the mode of binding of thiazolidinediones into FFAR1 and the mechanism of receptor activation.
    Helal MA; Darwish KM; Hammad MA
    Bioorg Med Chem Lett; 2014 Nov; 24(22):5330-6. PubMed ID: 25441945
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of new dual PPARγ-GPR40 agonists with robust antidiabetic activity: Design, synthesis and in combo drug evaluation.
    Hidalgo-Figueroa S; Navarrete-Vázquez G; Estrada-Soto S; Giles-Rivas D; Alarcón-Aguilar FJ; León-Rivera I; Giacoman-Martínez A; Miranda Pérez E; Almanza-Pérez JC
    Biomed Pharmacother; 2017 Jun; 90():53-61. PubMed ID: 28342366
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design, synthesis, and biological evaluation of novel pan agonists of FFA1, PPARγ and PPARδ.
    Li Z; Zhou Z; Deng F; Li Y; Zhang D; Zhang L
    Eur J Med Chem; 2018 Nov; 159():267-276. PubMed ID: 30296685
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thiazolidinediones as antidiabetic agents: A critical review.
    Nanjan MJ; Mohammed M; Prashantha Kumar BR; Chandrasekar MJN
    Bioorg Chem; 2018 Apr; 77():548-567. PubMed ID: 29475164
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recent Updates on Free Fatty Acid Receptor 1 (GPR-40) Agonists for the Treatment of Type 2 Diabetes Mellitus.
    Rani L; Grewal AS; Sharma N; Singh S
    Mini Rev Med Chem; 2021; 21(4):426-470. PubMed ID: 33100202
    [TBL] [Abstract][Full Text] [Related]  

  • 7. T2384, a novel antidiabetic agent with unique peroxisome proliferator-activated receptor gamma binding properties.
    Li Y; Wang Z; Furukawa N; Escaron P; Weiszmann J; Lee G; Lindstrom M; Liu J; Liu X; Xu H; Plotnikova O; Prasad V; Walker N; Learned RM; Chen JL
    J Biol Chem; 2008 Apr; 283(14):9168-76. PubMed ID: 18263587
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design, synthesis, and activity evaluation of GK/PPARγ dual-target-directed ligands as hypoglycemic agents.
    Lu J; Lei L; Huan Y; Li Y; Zhang L; Shen Z; Hu W; Feng Z
    ChemMedChem; 2014 May; 9(5):922-7. PubMed ID: 24737574
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PPARγ signaling and emerging opportunities for improved therapeutics.
    Wang S; Dougherty EJ; Danner RL
    Pharmacol Res; 2016 Sep; 111():76-85. PubMed ID: 27268145
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of an In Vitro Screening Platform for the Identification of Partial PPARγ Agonists as a Source for Antidiabetic Lead Compounds.
    Porskjær Christensen L; Bahij El-Houri R
    Molecules; 2018 Sep; 23(10):. PubMed ID: 30248999
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A review on the development in the field of NIDDM based thiazolidinedione PPARγ agonists.
    Banerjee PS; Samanta S
    Mini Rev Med Chem; 2013 Apr; 13(5):706-12. PubMed ID: 22512587
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis, molecular docking, dynamic simulation and pharmacological characterization of potent multifunctional agent (dual GPR40-PPARγ agonist) for the treatment of experimental type 2 diabetes.
    Hidalgo-Figueroa S; Rodríguez-Luévano A; Almanza-Pérez JC; Giacoman-Martínez A; Ortiz-Andrade R; León-Rivera I; Navarrete-Vázquez G
    Eur J Pharmacol; 2021 Sep; 907():174244. PubMed ID: 34116041
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis, docking, in vitro and in vivo antidiabetic activity of pyrazole-based 2,4-thiazolidinedione derivatives as PPAR-γ modulators.
    Naim MJ; Alam O; Alam MJ; Shaquiquzzaman M; Alam MM; Naidu VGM
    Arch Pharm (Weinheim); 2018 Apr; 351(3-4):e1700223. PubMed ID: 29400412
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis, biological evaluation, and molecular docking investigation of benzhydrol- and indole-based dual PPAR-γ/FFAR1 agonists.
    Darwish KM; Salama I; Mostafa S; Gomaa MS; Khafagy ES; Helal MA
    Bioorg Med Chem Lett; 2018 May; 28(9):1595-1602. PubMed ID: 29615345
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rational design and synthesis of some PPAR-γ agonists: Substituted benzylideneamino-benzylidene-thiazolidine-2,4-diones.
    Chhajed SS; Chaskar S; Kshirsagar SK; Haldar GM; Kar Mahapatra D
    Comput Biol Chem; 2017 Apr; 67():260-265. PubMed ID: 28193552
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design, synthesis and biological activity evaluation of a new class of 2,4-thiazolidinedione compounds as insulin enhancers.
    Huiying Z; Guangying C; Shiyang Z
    J Enzyme Inhib Med Chem; 2019 Dec; 34(1):981-989. PubMed ID: 31072232
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In silico design, chemical synthesis and toxicological evaluation of 1,3-thiazolidine-2,4-dione derivatives as PPARγ agonists.
    Alemán-González-Duhart D; Tamay-Cach F; Correa-Basurto J; Padilla-Martínez II; Álvarez-Almazán S; Mendieta-Wejebe JE
    Regul Toxicol Pharmacol; 2017 Jun; 86():25-32. PubMed ID: 28202347
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design, synthesis, and structure-activity relationship studies of novel 2,4,6-trisubstituted-5-pyrimidinecarboxylic acids as peroxisome proliferator-activated receptor gamma (PPARgamma) partial agonists with comparable antidiabetic efficacy to rosiglitazone.
    Seto S; Okada K; Kiyota K; Isogai S; Iwago M; Shinozaki T; Kitamura Y; Kohno Y; Murakami K
    J Med Chem; 2010 Jul; 53(13):5012-24. PubMed ID: 20527969
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cinnamic acid based thiazolidinediones inhibit human P450c17 and 3beta-hydroxysteroid dehydrogenase and improve insulin sensitivity independent of PPARgamma agonist activity.
    Arlt W; Neogi P; Gross C; Miller WL
    J Mol Endocrinol; 2004 Apr; 32(2):425-36. PubMed ID: 15072549
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design, Synthesis, and Biological Evaluation of Thiazolidine-2,4-dione Conjugates as PPAR-γ Agonists.
    Nazreen S; Alam MS; Hamid H; Shahar Yar M; Dhulap A; Alam P; Pasha MA; Bano S; Alam MM; Haider S; Kharbanda C; Ali Y; Pillai K
    Arch Pharm (Weinheim); 2015 Jun; 348(6):421-32. PubMed ID: 25900064
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.